ACTRN12618000977279: Open-label, dose escalation, first-in-human study of HLX20, an anti PD-L1 monoclonal antibody, in patients with metastatic or recurrent solid tumors who have failed standard therapy |
|
|
| Not yet recruiting | 1 | 30 | | | Shanghai Henlius Biotech, Inc., Shanghai Henlius Biotech, Inc. | Metastatic Solid Tumour for patients who have failed/not tolerated/not available standard treatment | | | | |
